Sofinnova acts as lead investor in ProQR Therapeutics cross over investment round
Clients Sofinnova Partners
Jones Day advised Sofinnova Partners, as lead investor, in the €42 million (US$58 million) Series A Convertible Preferred Stock private placement by ProQR Therapeutics B.V., a biotech company focused on the development of drugs to treat genetic disorders. The financing round included a number of U.S.-based cross over investors. The investment round was ahead of the IPO of ProQR Therapeutics on NASDAQ.